Parse Biosciences Expands Global Access to Israel
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced an agreement with Israel-based Ornat Biochemicals and Laboratory Equipment to extend Parse’s reach in the Middle East.
“The past year has represented a considerable leap forward for Parse, with demand growing significantly for our Evercode single cell sequencing solutions,” noted Parse CEO and co-founder Alex Rosenberg, Ph.D. “Partnering with a premier distributor in the Middle East positions us well in the region for continued growth.”
Parse’s agreement with Ornat will give researchers in Israel access to its full single cell portfolio, including Evercode™ Whole Transcriptome, Evercode TCR, Evercode Cell Fixation, Evercode Nuclei Fixation, Gene Capture, and the Parse Biosciences data analysis solution. The agreement bolsters Parse’s plan to offer its products in key international markets.
“Parse is accelerating the pace of single cell research with its Evercode technology. We're elated to partner with them to introduce this state of the art technology to the thriving biotech community in Israel,” said Ornat CEO, Eyal Lev.
About Parse Biosciences
Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.
With technology developed at The University of Washington by co-founders Alex Rosenberg and Charles Roco, Parse has raised over $50 million in capital and is now used by nearly 1,000 customers across the world. Its growing portfolio of products includes Evercode Whole Transcriptome, Evercode TCR, Gene Capture, and a data analysis solution.
Parse Biosciences is based in Seattle’s vibrant South Lake Union district, where it recently opened a 34,000 square foot headquarters and state-of-the-art laboratory. To learn more, please visit https://www.parsebiosciences.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005438/en/
Contact information
Jay Roberts, SRPR
jay@shevrushpr.com | 917.696.2142
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Connections, Local Flavors, and Luxurious Experiences Top the 2026 Bacardi Cocktail Trends Report17.11.2025 14:00:00 EET | Press release
The five defining trends set to reshape cocktail culture and the spirits industry in 2026 are highlighted in the seventh annual Bacardi Cocktail Trends Report. The Report released by Bacardi Limited, the largest privately held international spirits company, in partnership with The Future Laboratory (TFL), draws on data from Bacardi-led and third-party research, consumer surveys, bartender interviews and TFL’s trend forecasting to uncover the forces shaping cocktail experiences, flavor innovation, and drinking culture in the year ahead. The Report also reveals the cocktails which are set to be the most popular in 2026 and trends for younger Legal Drinking Age (LDA) consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117678098/en/ The 7th annual Bacardi Cocktail Trends Report unveils what and how people will be drinking in 2026. “Gen Z isn’t drinking less, they’re simply drinking earlier, lighter, and with more intent
AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth17.11.2025 14:00:00 EET | Press release
AdvanCell Pty Ltd (“AdvanCell”), a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the appointment of Philina Lee, PhD as Chief Executive Officer and member of the Board of Directors. Dr Lee will head AdvanCell’s US expansion, accelerating clinical, manufacturing, and partnership activities to advance lead clinical candidate 212Pb-ADVC001 and the company’s innovative radiopharmaceutical portfolio. She will assume her role from January 1, 2026, and will be based at the company’s new US headquarters near Boston/Cambridge, MA. “Philina brings a rare combination of global commercial leadership, deep radiopharmaceutical expertise, and an outstanding record of building high growth organizations and high-performance teams,” said Andrew Kay, Chair of AdvanCell. “Her leadership and experience positions AdvanCell to drive its next phase of growth, with the United States now a major strategic focus as the company advances 212Pb
MSCI Announces Baer Pettit to Retire as President17.11.2025 14:00:00 EET | Press release
MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced that C.D. Baer Pettit, President and Chief Operating Officer (COO), and a member of the Board of Directors, has informed the company that he will retire next year after more than 25 years in senior leadership roles. Mr. Pettit will continue to serve as President and a Director until March 1, 2026, and will remain as an advisor to the company for a period of time to ensure a smooth transition. Mr. Pettit joined MSCI in 2000 and has served in numerous senior leadership roles, including heading Client Coverage, Marketing and Index. He was appointed COO in 2015 and President in 2017, overseeing all products and operations, and he joined the Board of Directors in 2023. “Baer has been my longtime business partner, and he has played a pivotal role in shaping MSCI’s strategy and success,” said MSCI Chairman and CEO Henry Fernandez. “I would like to thank Bae
Arada to Acquire Majority Stake in £2.5bn Thameside West Development, Unlocking One of London’s Largest and Most Connected New Waterfront Neighbourhoods17.11.2025 13:58:00 EET | Press release
Arada, the UAE’s fastest-growing master developer, announces that it has agreed the acquisition of an 80% stake in Thameside West, a landmark waterfront mixed-use development located at the western end of London’s Royal Docks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117374964/en/ HH Sheikh Sultan bin Ahmed Al Qasimi, Chairman of Arada (centre) with members of the Arada and Keystone executive teams (Photo: AETOSWire) Master-planned by Foster + Partners, the vibrant new urban destination will deliver at least 5,000 homes, with half of the site dedicated to green space and a kilometre of active waterfront. Boasting unrivalled transport links, the integration of air, road, rail, river and tunnel links makes this one of the most connected sites in London. Spread over a 47-acre area – twice the size of the Hudson Yards mixed-use development in New York - Thameside West represents one of Europe’s largest and most strategi
Positive Phase 3 Results Support ZIIHERA ® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA ® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 13:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including cancers of the stomach, gastroesophageal junction, and esophagus. Both ZIIHERA plus TEVIMBRA and chemotherapy and ZIIHERA plus chemotherapy demonstrated clinically meaningful and highly statistically significant improvements in progression-free survival (PFS) compared to the control arm, trastuzumab plus chemotherapy. ZIIHERA plus TEVIMBRA and chemotherapy also demonstrated clinically meaningful and statistically significant improvements in overall survival (OS), and ZIIHERA plus chemotherapy demonstrated a clinically meaningful eff
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom